






Supplementary Figure S1. The genotyping diagrams of rs10754339 (A, B) and rs12976445 (C, D) by Sanger sequencing and PCR-RFLP assay.




Supplementary Figure S2. The flow diagram of the literature review process for the meta-analysis of rs10754339 and cancer risk (A) and the meta-analysis of rs12976445 and cancer risk (B).




Supplementary Figure S3. Forest plots for the meta-analysis of 10754339 and overall cancer risk under A vs. G in the total population (A) and the Chinese population (B). Forest plots for the meta-analysis of rs10754339 and breast cancer risk (C).





Supplementary Figure S4. Forest plots for the meta-analysis of rs12976445 and overall cancer risk under T vs. C in the total population (A), in the Asian population (B), based on PCR-RFLP (C), and in the Chinese population (D).



Supplementary Figure S5. *In silico* expression analysis of *B7-H4* mRNA expression in relation to different genotypes of rs10754339 (A) and *miR-125a* mRNA expression in relation to different genotypes of rs12976445 (B).

Supplementary Table S1. Characteristics of the included studies for the meta-analysis of rs10754339 and rs12976445

References (author, year)	Country/ethnicity	Cancer type	Genotyping assay ¹	Case, control (n)			HWE ²	Quality control ³ (Y/N)
				Total	A/G	AA/AG/GG		
rs10754339				Total	A/G	AA/AG/GG		
Asuman et al., 2013	USA/Caucasian	Breast cancer	PCR-RFLP	31, 30	54/8, 55/5	24/6/1, 26/3/1	0.167	Y
Asuman et al., 2017	Turkey/Caucasian	Bladder cancer	PCR-RFLP	62, 30	117/7, 47/13	55/7/0, 18/11/1	0.660	Y
Jin et al., 2022	China/Asian	Liver cancer	PCR-RFLP	480, 800	858/102, 1,443/157	384/90/6, 650/143/7	0.779	Y
Jin et al., 2022	China/Asian	Lung cancer	PCR-RFLP	550, 800	949/151, 1,443/157	409/131/10, 650/143/7	0.779	Y
Jin et al., 2022	China/Asian	Gastric cancer	PCR-RFLP	460, 800	797/123, 1,443/157	344/109/7, 650/143/7	0.779	Y
Li et al., 2009	China/Asian	Breast cancer	PCR-RFLP	287, 305	434/140, 493/117	159/116/12, 198/97/10	0.652	Y
Tsai et al., 2015	China/Asian	Breast cancer	PCR-RFLP	566/400	978/154, 720/80	420/138/8, 324/72/4	1.000	Y
Zhang et al., 2009	China/Asian	Breast cancer	PCR-RFLP	500, 504	753/247, 808/200	277/199/24, 324/160/20	0.965	Y
rs12976445				Total	T/C	TT/CT/CC		
Hosseini et al., 2018	Iranian/Asian	Colorectal cancer	TP-ARMS-PCR	373, 372	438/308, 431/313	118/202/53, 116/199/57	0.060	Y
Jin et al., 2022	China/Asian	Liver cancer	PCR-RFLP	480, 800	131/829, 165/1,435	10/111/359, 7/151/642	0.779	Y
Jin et al., 2022	China/Asian	Lung cancer	PCR-RFLP	550, 800	160/940, 165/1,435	15/130/405, 7/151/642	0.779	Y
Jin et al., 2022	China/Asian	Gastric cancer	PCR-RFLP	460, 800	109/811, 165/1,435	7/95/358, 7/151/642	0.779	Y
Mohan et al., 2018	Indian/Asian	Prostate cancer	PCR-RFLP	100, 100	99/101, 122/78	28/43/29, 37/48/15	0.930	Y
Morteza et al., 2020	Iranian/Asian	Prostate cancer	PCR-RFLP	150, 150	137/163, 143/157	28/81/41, 33/77/40	0.723	Y
Sun et al., 2021	China/Asian	Lung cancer	Taqman	503, 548	109/897, 114/982	8/93/402, 2/110/436	0.198	Y
Tomasz et al., 2020	Polish/Caucasian	Breast cancer	PCR-RFLP	175, 129	241/109, 173/85	80/81/14, 54/65/10	0.111	Y

Note. ¹PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; TP-ARMS-PCR, tetra-primer amplification refractory mutation systems polymerase chain reaction; ²Genotypic frequencies of rs10754339 and rs12976445 in normal controls was tested for departure from Hardy-Weinberg equilibrium (HWE) using the χ^2 test. ³Quality control was conducted when sample of cases and controls was genotyped.